Atalanta Therapeutics founded by UMass Medical School and three faculty members
Atalanta Therapeutics, a biotech founded by UMass Medical School and three faculty research scientists to pioneer treatment options for neurodegenerative diseases, has launched with financing by venture capital fund F-Prime Capital and strategic collaborations with Biogen and Genentech.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Medicine, Clinician, Faculty, Craig C. Mello, Anastasia Khvorova, RNA Therapeutics Institute, Aronin Lab, Program in Molecular Medicine, Neil Aronin,
Feb 29, 2024
Dean Flotte testifies at congressional hearing in support of gene therapy development
Dean Flotte testified in support of policies that would encourage and accelerate gene therapy for rare diseases, in a Feb. 29 hearing before the House Committee on Energy and Commerce’s Subcommittee on Health.
Read more
, School of Medicine, Medicine, Clinician, Faculty, Research, Rare Disease, Terence Flotte, Flotte Lab, Pediatrics, Li Weibo Institute for Rare Diseases Research, Aronin Lab, Gene Therapy Center, Neil Aronin, Latest News, Top Stories,
Jun 23, 2020
Yasaman Gholamalipour awarded fellowship by Huntington’s Disease Society of America
UMass Medical School postdoctoral associate Yasaman Gholamalipour, PhD, was awarded the Huntington’s Disease Society of America Berman-Topper Family HD Career Development Fellowship for 2020.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Medicine, Faculty, Postdoctoral Scholar, Rare Disease, Molecular, Cell and Cancer Biology, Neil Aronin,
May 15, 2023
MD/PhD student using NIH award to study onset of Huntington’s disease
MD/PhD student Jillian Belgrad has received an award from the National Institute of Neurological Disorders and Stroke to study the pathology that drives the development of Huntington’s disease symptoms.  
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Medicine, Student, Award, Research, Education, MD/PhD, Anastasia Khvorova, Radiology, RNA Therapeutics Institute, Aronin Lab, Program in Molecular Medicine, Neil Aronin, Latest News, Khvorova Lab, Top Stories,
Jul 17, 2019
UMMS scientists mark progress on Huntington’s disease research
Neil Aronin, MD, led an afternoon of presentations detailing advances made by scientists at UMass Medical School in the quest to find a treatment for Huntington’s disease. CHDI Foundation President Robi Blumenstein accepted a plaque in recognition of the foundation’s $13 million in support of Huntington’s research at the medical school.
Read more
, Graduate School of Biomedical Sciences, Faculty, Rare Disease, Neil Aronin,
